A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

Abstract Background We conducted an open-label, randomized, two-arm multi-center study to assess the efficacy and safety of paclitaxel versus paclitaxel + sorafenib in patients with locally advanced or metastatic HER2-negative breast cancer. Methods Patients were randomly assigned to receive either...

Full description

Bibliographic Details
Main Authors: Thomas Decker, Friedrich Overkamp, Siegfried Rösel, Arnd Nusch, Thomas Göhler, Martin Indorf, Jörg Sahlmann, Tanja Trarbach
Format: Article
Language:English
Published: BMC 2017-07-01
Series:BMC Cancer
Subjects:
Metastatic breast cancer
Paclitaxel
Sorafenib
Antineoplastic agents/chemotherapy
Online Access:http://link.springer.com/article/10.1186/s12885-017-3492-1

Internet

http://link.springer.com/article/10.1186/s12885-017-3492-1

Similar Items